Popular Blood Pressure Medication Recalled Due to Possible Contamination

• Blood pressure medication recalled for contamination
• Affected batches in the U.S.
• FDA classifies risk as low

According to USA TODAY, thousands of bottles of a prescription medication used to treat hypertension have been recalled in the United States due to possible contamination with another drug produced by the same company.

Glenmark Pharmaceuticals Inc., whose U.S. headquarters are in Elmwood Park, New Jersey, announced the recall of several batches of bisoprolol fumarate and hydrochlorothiazide tablets, marketed under the brand name Ziac.

The measure was taken after traces of ezetimibe were detected in reserve samples of the medication, according to a report published by the Food and Drug Administration (FDA).

The pharmaceutical company, whose global headquarters are in Mumbai, India, stated that both medications are manufactured at the same facilities and that cross-contamination may have occurred during production.

FDA reports cross-contamination

Blood pressure drug recalled for possible cross-contaminationhttps://t.co/a3gT6uPWy8

— This Is The Conversation Project (@th_conversation) December 7, 2025

Ezetimibe is a medication used to reduce cholesterol and is not part of Ziac’s formulation, prompting the immediate recall of the affected batches.

The official notice, published December 1, states that testing revealed minimal amounts of this compound, which is unrelated to blood pressure treatment.

The FDA classified the recall as Class III, indicating it is unlikely to cause serious health problems.

Nonetheless, health authorities and the company advised patients to check whether their medication bottles are among the recalled batches.

Blood pressure medication recall affects multiple batches

Bisoprolol with hydrochlorothiazide works by blocking beta-1 receptors in the heart, regulating heartbeats and lowering blood pressure.

The medication also increases urination to eliminate sodium and water from the body and relaxes blood vessels to reduce cardiac risks.

This treatment is common among hypertension patients, which has caused concern among users and medical professionals.

Authorities specified that the recall involves an unspecified number of batches in strengths ranging from 2.5 mg to 6.25 mg.

Manufacturing details and affected lots

The recalled products were manufactured in Madhya Pradesh, India, for U.S. distribution by Glenmark Pharmaceuticals.

Batches include bottles of 30, 100, and 500 tablets with expiration dates ranging from November 2025 to May 2026.

Among them are 30-tablet bottles from batch 17232401.

Additionally, the 500-tablet bottles include batches 17232401 and 17240974.

Recall remains under evaluation

USA TODAY reported that Glenmark Pharmaceuticals was contacted for more details about the recall.

So far, no official recommendations have been issued regarding next steps for patients.

According to GoodRx, patients are advised to check the batch number on their bottles.

They also recommend contacting a pharmacist and physician before discarding any recalled medication.

What affected patients should do

Users should carefully review the batch information and should not discontinue treatment without consulting a healthcare professional.

The lack of official guidance has raised questions among those who take Ziac.

Authorities remind the public of the importance of acting cautiously.

The recall will remain active while investigations determine whether additional batches are affected.

Blood pressure drug recall raises concerns about pharmaceutical oversight

No serious adverse effects linked to the recall have been reported so far.

The case underscores the importance of quality control standards.

Investigations will continue to determine how cross-contamination occurred.

The goal is to ensure that future products meet all safety regulations—an issue central to understanding this blood pressure drug contamination recall.